title: A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies.
abstract: OBJECTIVE
  It was the aim of this study to evaluate the safety of the optimized cryptic peptide TERT(572Y) in pretreated patients with advanced cancer.
  
  
  METHODS
  Nineteen patients with progressive and chemotherapy-refractory tumors received escalated doses (2-6 mg) of 2 subcutaneous injections of the optimized TERT(572Y) peptide followed by 4 subcutaneous injections of the native TERT(572) peptide every 3 weeks. Both TERT peptides were coinjected with adjuvant Montanide ISA51. Toxicity was evaluated every 3 weeks and peptide-specific CD8+ cells were detected by flow cytometry using TERT(572Y) tetramers.
  
  
  RESULTS
  Fourteen out of 19 patients completed the vaccination program. No grade III/IV toxicity was observed. Grade I anemia was observed in 4 patients and local skin reaction at the injection site in 11 patients. Other nonhematologic toxicities were mild, and no late toxicity was observed after a median postvaccination follow-up period of 10.7 months. There was no dose-limiting toxicity. Peripheral blood TERT(572Y)-specific CD8+ lymphocytes were detected in 13 out of 14 evaluable patients after 2 injections with the optimized TERT(572Y) peptide. There was no complete or partial response, but 4 patients (21%) with persistent TERT(572Y)-specific CD8+ experienced stable disease for a median of 10.5 months.
  
  
  CONCLUSIONS
  TERT(572Y) peptide vaccine is well tolerated and effective in eliciting specific TERT(572Y) CD8+ lymphocytes in pretreated cancer patients, demonstrating that cryptic peptides could be used in cancer immunotherapy.
authors.affiliation: Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece. georgoul@med.uoc.gr
authors.forename: D
authors.initials: D
authors.lastname: Mavroudis
authors.forename: I
authors.initials: I
authors.lastname: Bolonakis
authors.forename: S
authors.initials: S
authors.lastname: Cornet
authors.forename: G
authors.initials: G
authors.lastname: Myllaki
authors.forename: P
authors.initials: P
authors.lastname: Kanellou
authors.forename: A
authors.initials: A
authors.lastname: Kotsakis
authors.forename: A
authors.initials: A
authors.lastname: Galanis
authors.forename: I
authors.initials: I
authors.lastname: Nikoloudi
authors.forename: M
authors.initials: M
authors.lastname: Spyropoulou
authors.forename: J
authors.initials: J
authors.lastname: Menez
authors.forename: I
authors.initials: I
authors.lastname: Miconnet
authors.forename: M
authors.initials: M
authors.lastname: Niniraki
authors.forename: P
authors.initials: P
authors.lastname: Cordopatis
authors.forename: K
authors.initials: K
authors.lastname: Kosmatopoulos
authors.forename: V
authors.initials: V
authors.lastname: Georgoulias
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000368:Aged; D000595:Amino Acid Sequence; D001324:Autoantigens / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000031:analogs & derivatives; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D009829:Oleic Acids / Q000008:administration & dosage; D010455:Peptides / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D019098:Telomerase / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D001324:Autoantigens; D019496:Cancer Vaccines; D009829:Oleic Acids; D010455:Peptides; C477385:montanide ISA 51; D008353:Mannitol; D019098:Telomerase